MULTICENTER PHASE-II STUDY OF BREQUINAR SODIUM IN PATIENTS WITH ADVANCED LUNG-CANCER

被引：61

作者：

MAROUN, J

RUCKDESCHEL, J

NATALE, R

MORGAN, R

DALLAIRE, B

SISK, R

GYVES, J

机构：

[1] DUPONT PHARMACEUT CO,POB 80026,WILMINGTON,DE 19880

[2] OTTAWA REG CANCER CTR,OTTAWA,ON,CANADA

[3] ALBANY MED CTR,ALBANY,NY

[4] UNIV MICHIGAN,ANN ARBOR,MI 48109

[5] CITY HOPE NATL MED CTR,DUARTE,CA 91010

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 1993年 / 32卷 / 01期

关键词：

BREQUINAR SODIUM; LUNG CANCER; PHASE-II;

D O I：

10.1007/BF00685878

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A total of 53 patients with advanced lung cancer [non-small-cell (NSC), 21; small-cell (SC), 32] were treated with brequinar sodium. All of the NSC patients were chemotherapy-naive, but 31/32 (97%) SC patients had failed a multiagent chemotherapy program prior to study entry. Brequinar was given intravenously at a median weekly dose of 1200 mg/m2. The toxicity was moderate, with 19 patients (36%) experiencing grade 3 or 4 toxicity. Objective responses were observed in one NSC and two SC patients. We conclude that at this dose and on this schedule, brequinar does not have sufficient activity in patients with NSC or in patients with previously treated SC to warrant further evaluation. However, since responses were observed in previously treated SC lung-cancer patients, further evaluation in chemotherapy-naive patients may be warranted.

引用

页码：64 / 66

页数：3

共 10 条

[1]

ARMAND JP, 1987, P AN M AM SOC CLIN, V6, P46

[2]

ARTEAGA CL, 1989, CANCER RES, V49, P4648

[3] A PHASE I CLINICAL AND PHARMACOKINETIC STUDY OF BREQUINAR SODIUM, DUP-785 (NSC-368390), USING A WEEKLY AND A BIWEEKLY SCHEDULE [J].

BORK, E ;

VEST, S ;

HANSEN, HH .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (10) :1403-1411

[4]

CHEN SF, 1986, CANCER RES, V46, P5014

[5]

CURRIE V, 1988, P AN M AM SOC CLIN, V7, P76

[6]

DALLAIRE B, 1991, CLIN RES, V39, P375

[7]

DEXTER DL, 1985, CANCER RES, V45, P5563

[8]

NOE DA, 1990, CANCER RES, V50, P4595

[9] PHASE-I STUDY OF BREQUINAR SODIUM (NSC-368390) IN PATIENTS WITH SOLID MALIGNANCIES [J].

SCHWARTSMANN, G ;

DODION, P ;

VERMORKEN, JB ;

HUININK, WWT ;

JOGGI, J ;

WINOGRAD, B ;

GALL, H ;

SIMONETTI, G ;

VANDERVIJGH, WJF ;

VANHENNIK, MB ;

CRESPEIGNE, N ;

PINEDO, HM .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1990, 25 (05) :345-351

[10]

1979, WHO OFFICAL PUBLICAT, V45

← 1 →